Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Drugs Aging. 2021 Apr;38(4):285-299. doi: 10.1007/s40266-021-00837-7. Epub 2021 Feb 23.
Stroke is the leading cause of seizures and epilepsy in older adults. Patients who have larger and more severe strokes involving the cortex, are younger, and have acute symptomatic seizures and intracerebral haemorrhage are at highest risk of developing post-stroke epilepsy. Prognostic models, including the SeLECT and CAVE scores, help gauge the risk of epileptogenesis. Early electroencephalogram and blood-based biomarkers can provide information additional to the clinical risk factors of post-stroke epilepsy. The management of acute versus remote symptomatic seizures after stroke is markedly different. The choice of an ideal antiseizure medication should not only rely on efficacy but also consider adverse effects, altered pharmacodynamics in older adults, and the influence on the underlying vascular co-morbidity. Drug-drug interactions, particularly those between antiseizure medications and anticoagulants or antiplatelets, also influence treatment decisions. In this review, we describe the epidemiology, risk factors, biomarkers, and management of seizures after an ischaemic or haemorrhagic stroke. We discuss the special considerations required for the treatment of post-stroke epilepsy due to the age, co-morbidities, co-medication, and vulnerability of stroke survivors.
中风是老年人癫痫和癫痫发作的主要原因。那些大脑皮层出现更大、更严重中风,年龄较小,有急性症状性癫痫发作和脑出血的患者,发生中风后癫痫的风险最高。包括 SeLECT 和 CAVE 评分在内的预测模型有助于评估癫痫发生的风险。早期脑电图和基于血液的生物标志物可以提供除中风后癫痫的临床危险因素之外的信息。急性与远程症状性癫痫发作的管理有显著不同。理想抗癫痫药物的选择不仅应依赖于疗效,还应考虑老年人的药物动力学改变以及对潜在血管合并症的影响。药物相互作用,特别是抗癫痫药物与抗凝剂或抗血小板药物之间的相互作用,也会影响治疗决策。在这篇综述中,我们描述了缺血性或出血性中风后癫痫的流行病学、危险因素、生物标志物和管理。我们讨论了由于年龄、合并症、合并用药和中风幸存者的脆弱性,中风后癫痫治疗所需的特殊考虑因素。